Parabilis Raises Record $770.5 Million IPO to Advance Zolucatetide After 100% Tumor Reductions
Updated
Updated · Harvard Gazette · Jun 22
Parabilis Raises Record $770.5 Million IPO to Advance Zolucatetide After 100% Tumor Reductions
1 articles · Updated · Harvard Gazette · Jun 22
Summary
$770.5 million from Parabilis’ June 10 IPO will fund further development of zolucatetide and other cancer programs, marking a record haul for a venture-backed biotech company.
Zolucatetide drove the listing after Phase 1 and 2 data showed tumor reductions in 100% of desmoid tumor patients, helping validate its first-in-class approach against beta-catenin.
The drug builds on Greg Verdine’s “helicon” or stapled-peptide technology, designed to slip inside cells and bind proteins long considered undruggable.
Parabilis, formerly Fog Pharmaceuticals, already won FDA fast-track designation for zolucatetide in desmoid tumors in November 2025, giving the company a clearer regulatory path as it deploys the IPO proceeds.
The fundraising also highlights broader investor interest in novel cancer platforms after another Verdine-linked drug, daraxonrasib, roughly doubled pancreatic-cancer survival from 6.7 months to 13.2 months in Phase 3.
After cracking pancreatic cancer, which 'undruggable' diseases could this revolutionary drug technology conquer next?
Verdine’s drugs offer new hope against cancer, but will they be accessible to everyone or only the wealthy?
Can AI replicate the human intuition behind these cancer breakthroughs, or is 'crazy' science uniquely human?
Parabilis Medicines Raises $670 Million in Landmark IPO, Accelerates Zolucatetide and Helicon™ Platform
Overview
Parabilis Medicines recently completed a record-setting $670 million IPO, shattering its own fundraising expectations multiple times. This strong market demand and investor belief in Parabilis’s potential signaled renewed confidence in drug developers after a slow IPO period last year. The IPO also showed that the biotech IPO window is now open for companies with real clinical programs. Parabilis began trading under the ticker 'PBLS,' offering 33.5 million shares at $20 each, and saw its stock price surge 58% on the first full trading day. These achievements highlight Parabilis’s strong position and the growing optimism in the biotech sector.